Ferris Rebecca, Maung Tun, Atkins Christopher, Terrington Dayle, Clark Allan, Manivarmane Surya Prasad, Wilson Andrew
Department of Respiratory Medicine, Norfolk and Norwich University Hospital NHS Foundation Trust, Colney Lane, Norwich, Norfolk, NR4 7UY.
Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, Norfolk, UK, NR4 7TJ.
Sarcoidosis Vasc Diffuse Lung Dis. 2023 Sep 13;40(3):e2023041. doi: 10.36141/svdld.v40i3.13253.
Patient related outcomes are important in sarcoidosis but the medium-term repeatability of the key patient reported outcome measure is not known. We aimed to test the repeatability of the Fatigue Assessment Scale (FAS), Short Form 6-Dimension (SF-6D), and King's Sarcoidosis Questionnaire (KSQ) in free living people with sarcoidosis associated fatigue.
Twelve people with sarcoidosis associated fatigue completed the FAS, short form 36 questionnaire (SF-36) and the KSQ at baseline and 12 weeks. The SF-6D utility was calculated from the SF-36. The difference between baseline and 12 week assessments was measured.
The interclass correlation (95% confidence interval) showed good agreement between the baseline and 3 months measurements: FAS 0.91 (0.74, 0.71), SF-36 0.98 (0.94, 1), KSQ 0.98 (0.93, 0.99), SF-6D utility 0.98 (0.93, 0.99). The baseline (standard deviation) FAS was 27.83 (5.86) and at 12 weeks was 27.25 (7.55) representing 0.58 difference (95% CI for difference (-1.89, 3.06)), SF-6D utility was 0.69 (0.16) at baseline and 0.68 (0.17) after 3 months representing at 0.00 (-0.03, 0.03) difference and corresponding values for KSQ were 59.12 (18.68) and 56.91 (27.26) with a difference of -1.87 (5.49,1.76).
There was good repeatability of FAS, SF-36, SF-6D and KSQ in free living people with sarcoidosis associated fatigue. Fatigue, general and disease specific health related quality of life showed no significant change over a 12 week period. Studies identifying changes in these outcomes can confidently report a true change and not measurement error or regression to the mean.
患者相关结局在结节病中很重要，但关键患者报告结局指标的中期可重复性尚不清楚。我们旨在测试疲劳评估量表（FAS）、简短形式6维度量表（SF - 6D）和国王结节病问卷（KSQ）在患有结节病相关疲劳的自由生活人群中的可重复性。
12名患有结节病相关疲劳的患者在基线和12周时完成了FAS、简短形式36问卷（SF - 36）和KSQ。SF - 6D效用值由SF - 36计算得出。测量了基线和12周评估之间的差异。
组内相关系数（95%置信区间）显示基线和3个月测量之间具有良好的一致性：FAS为0.91（0.74，0.71），SF - 36为0.98（0.94，1），KSQ为0.98（0.93，0.99），SF - 6D效用值为0.98（0.93，0.99）。基线时（标准差）FAS为27.83（5.86），12周时为27.25（7.55），差异为0.58（差异的95%置信区间为（-1.89，3.06）），SF - 6D效用值基线时为0.69（0.16），3个月后为0.68（0.17），差异为0.00（-0.03，0.03），KSQ的相应值分别为59.12（18.68）和56.91（27.26），差异为 - 1.87（5.49，1.76）。
FAS、SF - 36、SF - 6D和KSQ在患有结节病相关疲劳的自由生活人群中具有良好的可重复性。疲劳、总体及疾病特异性健康相关生活质量在12周内无显著变化。确定这些结局变化的研究可以可靠地报告真实变化，而不是测量误差或均值回归。
